GRI Bio vs Nkarta
GRI and NKTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRI and NKTX compare
Nkarta is the larger company, worth 30 times as much as GRI Bio ($89.5M against $3.0M).
Nkarta scores higher on the StockData Score (7 against 6 for GRI Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRI | NKTX |
|---|---|---|
| Size and price | ||
| Market cap | $3.0M | $89.5M |
| Share price | $1.35 | $1.25 |
| Change, 1 year | −97.1% | −33.2% |
| Change, 5 years | −100% | −92.3% |
| Beta (5Y) | 1.18 | 3.10 |
| Employees | 4 | 108 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× (better) | 0.4× |
| FCF yield | – | −105% |
| Profitability | ||
| Return on equity | −142% | −38.8% (better) |
| Return on invested capital | – | −157% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.30 (better) | 7.98 |
| Altman Z-score | −6.93 | −3.08 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 4.3% | 82.9% |
| Held by insiders | 26.2% | 35.8% |
| Insider net buying, 12 months | – | −$70.4K |
| Short interest, % of float | 4.1% | 8.3% |
Go deeper
- GRI stock overview
- GRI income statement
- GRI valuation and score
- NKTX stock overview
- NKTX income statement
- NKTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.